In The News

For Media

Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.

Argos Therapeutics Reports Third Quarter 2015 Financial Results and Operational Highlights
Read more

Argos Therapeutics to Host Third Quarter 2015 Financial Results Conference Call on Monday, November 16, 2015
Read more

Argos Therapeutics to Participate in 3rd Annual EU Advanced Therapies Investor Day
Read more

Argos Therapeutics to Participate in the 3rd International mRNA Health Conference
Read more

Argos Therapeutics to Host Review of the Current Clinical Research Landscape in Kidney Cancer Following the 40th Congress of the European Society for Medical Oncology, With Insights From Dr. Charles Drake of Johns Hopkins Sidney Kimmel Cancer Center
Read more

Argos Therapeutics to Participate in 2015 Stem Cell Meeting on the Mesa
Read more

Robert F. Carey Appointed to the Board of Directors of Argos Therapeutics
Read more

Argos Therapeutics to Participate in FBR Second Annual Healthcare Conference
Read more

Argos Therapeutics to Participate in Stem Cells and Regenerative Medicine Congress 2015
Read more

Argos Therapeutics Awarded Patent for Its Experimental Individualized Immunotherapy for the Treatment of HIV Infection
Read more